Xinyue Huang

Xinyue Huang

Auto-generated profile, based on publicly available information

Xinyue Huang

Department of Geriatrics, The First Affiliated Hospital of China Medical University, 110001 Shenyang, Liaoning, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2023 in Circulation Research
Verified
Journal Article
Open access
YZYing Zhang
Ying Zhang
NZNaijin Zhang
Naijin Zhang
YZYuanming Zou
Yuanming Zou
CSChunyu Song
Chunyu Song
KCKexin Cao
Kexin Cao
YSYingxian Sun
Yingxian Sun
Background: Hypertension can lead to podocyte damage and subsequent apoptosis, eventually resulting in glomerulosclerosis. Although alleviating podocyte apoptosis has clinical significance for the treatment of hypertensive nephropathy, an effective therapeutic target has not yet been identified. The function of septin4, a proapoptotic protein and an important marker of organ damage, is regulated by post-translational modification. However, the exact role of septin4 in regulating podocyte apoptosis and its connection to hypertensive renal damage remains unclear. Methods: We investigated the function and mechanism of septin4 in hypertensive nephropathy to discover a theoretical basis for targeted treatment. Mouse models including Rosa 26 (Gt(ROSA)26Sor)- SIRT2 (silent mating type information regulation 2 homolog-2)-Flag-TG (transgenic) ( SIRT2 -TG) mice SIRT2 -knockout, and septin4 -K174Q mutant mice, combined with proteomic and acetyl proteomics analysis, followed by multiple molecular biological methodologies, were used to demonstrate mechanisms of SIRT2-mediated deacetylation of septin4-K174 in hypertensive nephropathy. Results: Using transgenic septin4 -K174Q mutant mice treated with the antioxidant Tempol, we found that hyperacetylation of the K174 site of septin4 exacerbates Ang II (angiotensin II)– induced hypertensive renal injury resulting from oxidative stress. Proteomics and Western blotting assays indicated that septin4-K174Q activates the cleaved-PARP1 (poly [ADP-ribose] polymerase family, member 1)-cleaved-caspase3 pathway. In septin4-knockdown human renal podocytes, septin4-K174R, which mimics deacetylation at K174, rescues podocyte apoptosis induced by Ang II. Immunoprecipitation and mass spectrometry analyses identified SIRT2 as a deacetylase that interacts with the septin4 GTPase domain and deacetylates septin4-K174. In Sirt2 -deficient mice and SIRT2-knockdown renal podocytes, septin4-K174 remains hyperacetylated and exacerbates hypertensive renal injury. By contrast, in Rosa26-Sirt2-Flag (SIRT2-TG) mice and SIRT2-knockdown renal podocytes reexpressing wild-type SIRT2, septin4-K174 is hypoacetylated and mitigates hypertensive renal injury. Conclusions: Septin4, when activated through acetylation of K174 (K174Q), promotes hypertensive renal injury. Septin4-K174R, which mimics deacetylation by SIRT2, inhibits the cleaved-PARP1-cleaved-caspase3 pathway. Septin4-K174R acts as a renal protective factor, mitigating Ang II–induced hypertensive renal injury. These findings indicate that septin4-K174 is a potential therapeutic target for the treatment of hypertensive renal injury.

25 July 2023 in The FASEB Journal
Verified
Journal Article
Open access
DWDong Wang
Dong Wang
YZYuanming Zou
Yuanming Zou
XHXinyue Huang
Xinyue Huang
ZYZeyu Yin
Zeyu Yin
MLMohan Li
Mohan Li
ZNZhang Naijin
Zhang Naijin
The ubiquitin‐proteasome system is a crucial mechanism for regulating protein levels in cells, with substrate‐specific E3 ubiquitin ligases serving as an integral component of this system. Among these ligases are SMAD‐specific E3 ubiquitin‐protein ligase 1 (SMURF1) and SMAD‐specific E3 ubiquitin‐protein ligase 2 (SMURF2), which belong to the neural precursor cell‐expressed developmentally downregulated 4 (NEDD4) subfamily of Homologous to E6‐AP COOH terminus (HECT)‐type E3 ligases. As E3 ligases, SMURFs have critical functions in regulating the stability of multiple proteins, thereby maintaining physiological processes such as cell migration, proliferation, and apoptosis. The occurrence of many diseases is attributed to abnormal cell physiology and an imbalance in cell homeostasis. It is noteworthy that SMURFs play pivotal roles in disease progression, with the regulatory functions being complex and either facilitative or inhibitory. In this review, we elucidate the mechanisms by which SMURF1 and SMURF2 can regulate disease progression in non‐cancerous diseases. These significant findings offer potential novel therapeutic targets for various diseases and new avenues for research on SMURF proteins.

8 May 2023 in Cell Discovery
Verified
Journal Article
Open access
PDF file
ZNZhang Naijin
Zhang Naijin
YZYing Zhang
Ying Zhang
YCYong Chen
Yong Chen
HQHao Qian
Hao Qian
BWBoquan Wu
Boquan Wu
YSYingxian Sun
Yingxian Sun

18 October 2022 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
XLXinxin Lu
Xinxin Lu
XHXinyue Huang
Xinyue Huang
HXHaiqi Xu
Haiqi Xu
SLSaien Lu
Saien Lu
SYShilong You
Shilong You
LZLijun Zhang
Lijun Zhang
Acute lymphoblastic leukemia (ALL) has been a huge threat for people's health and finding effective target therapy is urgent and important. WWP2, as one of E3 ubiquitin ligase, is involved in many biological processes by specifically binding to substrates. PARP1 plays a role in cell apoptosis and is considered as a therapeutic target of certain cancers. In this study, we firstly found that WWP2 expressed higher in newly diagnosed ALL patients comparing with complete remission (CR) ALL patients and normal control people, and WWP2 in relapse ALL patients expressed higher than normal control people. WWP2 expression was related with the FAB subtype of ALL and the proportion of blast cells in bone marrow blood tested by flow cytometry. We demonstrated knockout WWP2 inhibited the ALL growth and enhanced apoptosis induced by Dox in vitro and vivo for the first time. WWP2 negatively regulated and interacted with PARP1 and WWP2 mechanically degraded PARP1 through polyubiquitin-proteasome pathway in ALL. These findings suggested WWP2 played a role in ALL development as well as growth and apoptosis, and also displayed a regulatory pathway of PARP1, which provided a new potential therapeutic target for the treatment of ALL.

26 September 2025 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Open access
YGYixin Guo
Yixin Guo
SWShuang Wang
Shuang Wang
XHXinyue Huang
Xinyue Huang
YZYanhua Zheng
Yanhua Zheng
FLFang Liu
Fang Liu
XWXiaoxue Wang
Xiaoxue Wang
Single-cell RNA sequencing (scRNA-seq) technology, also known as single-cell transcriptome sequencing, has become a key tool in biology and medicine, enabling deeper insights into cellular diversity and disease mechanisms. Since 2009 when scRNA-seq technology was first introduced, many technologies have been developed and improved, with a wide range of applications in haematopoietic malignancies, solid tumours, and other fields. These technologies have been used by researchers to map transcriptomes, study intra- and inter-cellular heterogeneity, investigate tumour microenvironments, analyse specific cellular subpopulations, and assist in clinical studies. This review categorises scRNA-seq on the basis of different single-cell amplification techniques, provides an overview of the principles of currently commonly used scRNA-seq techniques, discusses the application of scRNA-seq in the context of haematopoietic malignancies, and will hopefully play a role in the future development of single-cell sequencing technologies.